EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 11-Sep-2025 15:11 ET (11-Sep-2025 19:11 GMT/UTC)

1-Aug-2025

Hollings researchers show how natural language processing can aid doctors

Medical University of South Carolina
Peer-Reviewed Publication

A team led by researchers at MUSC Hollings Cancer Center developed an artificial intelligence tool that uses natural language processing to identify the original cancer type of patients with brain metastases by analyzing their doctors’ clinical notes. The model outperformed standard diagnostic codes, accurately determining the primary cancer type in over 90% of cases, which can improve research efforts and enable more precise care. The lightweight, scalable tool could streamline cancer care and research by unlocking critical insights buried in electronic health records.

Journal: JCO Clinical Cancer Informatics

1-Aug-2025

Scientists discover how leukemia virus stays hidden in the body – a key to future treatments

Kumamoto University
Peer-Reviewed Publication

A research team from Kumamoto University has made a groundbreaking discovery that reveals how the human T-cell leukemia virus type 1 (HTLV-1) silently persists in the body, potentially laying the foundation for new therapeutic approaches. Their findings, published on May 13, 2025, in Nature Microbiology, identify a previously unknown genetic “silencer” element that keeps the virus in a dormant, undetectable state.

Journal: Nature Microbiology
Funder: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Grant for Joint Research Project of the Institute of Medical Science, the University of Tokyo,, JST-Mirai Program, Japan Society for the Promotion of Science, Shinnihon Foundation of Advanced Medical Treatment Research

1-Aug-2025

Study reports final clinical trial data for advanced kidney cancer treatment

Vanderbilt University Medical Center
Peer-Reviewed Publication

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

Journal: Nature Medicine
Funder: MSD France

31-Jul-2025

New AI tool illuminates “dark side” of the human genome

Salk Institute
Peer-Reviewed Publication

Salk Institute researchers launch machine learning framework ShortStop, which explores overlooked DNA regions in the "dark side" of the human genome in search of microproteins that may play roles in health or disease. They already used ShortStop to analyze a lung cancer dataset and find microproteins that may serve as biomarkers or therapeutic targets.

Journal: BMC Methods

31-Jul-2025

Support for continued use of nasogastric tube after oesophageal cancer surgery

Uppsala University
Peer-Reviewed Publication

In the largest Nordic study to date concerning oesophageal cancer surgery, the researchers found clear evidence that decompression with a nasogastric tube is associated with less serious complications. Their results challenge a trend of declining use of the nasogastric tube after major surgical procedures. The study was led from Uppsala University and has now been published in Lancet Regional Health Europe.

Journal: The Lancet Regional Health - Europe
Funder: Cancerfonden, Nordic Cancer Union

31-Jul-2025

CCNY team discovers potential chemo-induced cognitive changes in cancer survivors

City College of New York
Peer-Reviewed Publication

Researchers at The City College of New York have linked chemotherapy treatment to lasting cognitive changes in rats – potentially shading light, for the first time, on cognitive problems some cancer survivors experience long after treatment ends. Entitled “Chemotherapy treatment alters DNA methylation patterns in the prefrontal cortex of female rat brain,” the study appears in the journal Nature: Scientific Reports.

Journal: Scientific Reports

31-Jul-2025

Understanding what makes some bladder cancers resistant to chemotherapy

Baylor College of Medicine
Peer-Reviewed Publication

About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors resist chemotherapy and identify better ways to treat those cancers, researchers at Baylor College of Medicine have conducted a detailed molecular analysis of MIBC tumors. The results offer potential new ways to identify which patients will benefit from chemotherapy and reveal possible new treatment strategies.

Journal: Cell Reports Medicine

31-Jul-2025

Ovarian tumor immune landscapes offer clues to better therapy

Ludwig Institute for Cancer Research
Peer-Reviewed Publication

The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies. But little was known about how the immune landscape of tumors changes when patients relapse—as they frequently do—or how those changes influence responses to subsequent therapy, which tend to be dismal.

Journal: Cancer Cell
Funder: Ludwig Institute for Cancer Research, U.S. Department of Defense, Hoffmann-La Roche AG

31-Jul-2025

Big data begins to crack the cold case of endometriosis

University of California - San Francisco
Peer-Reviewed Publication

Scientists at UCSF have found that endometriosis — a painful chronic disease affecting 10% of women that often goes undiagnosed — often occurs alongside conditions like cancer, Crohn's disease, and migraine.

The research could improve how endometriosis is diagnosed and, ultimately, how it is treated; and it paints the sharpest portrait yet of a condition that is as mysterious as it is prevalent.

Journal: Cell Reports Medicine
Funder: NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development

31-Jul-2025

Not all low-grade prostate cancers are low risk

Weill Cornell Medicine
Peer-Reviewed Publication

A new study reveals that some men who are diagnosed with “Grade Group one” (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell Medicine, University Hospitals Cleveland and Case Western University. The researchers conclude that relying on biopsy grade alone can lead to underestimating disease risk and misclassifying individuals who may benefit from definitive treatment with either surgery or radiation. Biopsies test only small areas of the prostate, so they can miss more advanced or aggressive cancer cells, providing an incomplete picture.

Journal: JAMA Oncology